- Home
- SCSC vs ABUS Comparison
SCSC vs ABUS Comparison
Compare SCSC & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCSC
- ABUS
- Stock Information
- Founded
- SCSC 1992
- ABUS 2005
- Country
- SCSC United States
- ABUS United States
- Employees
- SCSC N/A
- ABUS 44
- Industry
- SCSC Retail: Computer Software & Peripheral Equipment
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- SCSC Technology
- ABUS Health Care
- Exchange
- SCSC Nasdaq
- ABUS Nasdaq
- Market Cap
- SCSC 892.3M
- ABUS 828.9M
- IPO Year
- SCSC 1994
- ABUS N/A
- Fundamental
- Price
- SCSC $39.53
- ABUS $4.34
- Analyst Decision
- SCSC Hold
- ABUS Strong Buy
- Analyst Count
- SCSC 1
- ABUS 2
- Target Price
- SCSC $43.00
- ABUS $5.00
- AVG Volume (30 Days)
- SCSC 167.5K
- ABUS 1.1M
- Earning Date
- SCSC 11-06-2025
- ABUS 11-13-2025
- Dividend Yield
- SCSC N/A
- ABUS N/A
- EPS Growth
- SCSC 1.79
- ABUS N/A
- EPS
- SCSC 3.20
- ABUS N/A
- Revenue
- SCSC $3,004,880,000.00
- ABUS $14,606,000.00
- Revenue This Year
- SCSC $6.48
- ABUS $138.02
- Revenue Next Year
- SCSC $4.66
- ABUS N/A
- P/E Ratio
- SCSC $12.35
- ABUS N/A
- Revenue Growth
- SCSC N/A
- ABUS 116.64
- 52 Week Low
- SCSC $28.75
- ABUS $2.71
- 52 Week High
- SCSC $53.90
- ABUS $5.10
- Technical
- Relative Strength Index (RSI)
- SCSC 42.80
- ABUS 45.67
- Support Level
- SCSC $37.36
- ABUS $4.08
- Resistance Level
- SCSC $40.24
- ABUS $4.87
- Average True Range (ATR)
- SCSC 1.67
- ABUS 0.23
- MACD
- SCSC -0.24
- ABUS -0.05
- Stochastic Oscillator
- SCSC 59.13
- ABUS 32.28
About SCSC ScanSource Inc.
ScanSource Inc provides value-added services for technology manufacturers and sells to resellers in specialty technology markets. The firm's operations are organized in two segments: Specialty Technology Solutions and Modern Communications and Cloud. It generates maximum revenue from the Specialty Technology Solutions segment. The Specialty Technology Solutions segment includes the company's business in mobility and barcode, POS, payments, security and networking technologies. Geographically, it derives a majority of revenue from the United States.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.